An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children

Xiaoping Luo, Ling Hou, Yan Zhong, Cheng You, Yu Yang, Xian Wu, Pin Li, Shasha Zhou, Wenjuan Qiu, Huiwen Zhang, Ying Liu, Ye Qian, Feihong Luo, Ruoqian Cheng, Yuhua Hu, Haihong Gong, Qing Wang, Zhuangjian Xu, Hongwei Du, Feiyu Lu, Junfen Fu, Xuefeng Chen, Winston Wang, Ziheng Guo, Xiaoping Luo, Ling Hou, Yan Zhong, Cheng You, Yu Yang, Xian Wu, Pin Li, Shasha Zhou, Wenjuan Qiu, Huiwen Zhang, Ying Liu, Ye Qian, Feihong Luo, Ruoqian Cheng, Yuhua Hu, Haihong Gong, Qing Wang, Zhuangjian Xu, Hongwei Du, Feiyu Lu, Junfen Fu, Xuefeng Chen, Winston Wang, Ziheng Guo

Abstract

Background: Leuprorelin is an analog of gonadotropin-releasing hormone that is used for the therapy of central precocious puberty (CPP). The aims of this prospective, open label, multicenter clinical trial were to establish its efficacy and safety during long-term use.

Methods: Patients, who were all children, were treated with 1.88 to 3.75 mg leuprorelin subcutaneously once every 4 weeks for a total of 96 weeks between 2015 and 2018. The primary endpoint was the rate of occurrence of adverse events (AEs) and the secondary endpoint was no progression in the Tanner stage or regression by week 96 compared to baseline.

Results: A total of 307 CPP patients, 305 (99.3%) females and 2 males (0.7%), completed the 96-weeks of treatment. Due to limited data for male patients, they are not discussed in the efficacy results. Treatment-emergent AEs (TEAEs) were reported for 252 (82.1%) patients, mostly (79.5%) being mild or moderate and only 33 (10.7%) of patients experienced TEAEs related to leuprorelin therapy. The most frequent (>2%) drug-related TEAEs were injection site induration (4.6%, 14/307) and vaginal bleeding (2.3%, 7/305). After treatment, 83.5% of patients had regression or no progression in the Tanner stage (95% confidence interval: 78.68%, 87.62%) and the majority had decreased gonadotropin-releasing hormone-stimulated peak luteinizing hormone and follicle-stimulating hormone concentrations, as well as reduced sex hormone concentrations and a reduction in the bone age/chronological age ratio compared to baseline.

Conclusions: The trial revealed that CPP was effectively treated in most patients who received leuprorelin for nearly 2 years. Any drug-related AEs were reported with low incidence (<5%) and were consistent with the known safety profile of leuprorelin.

Trial registration: The trial was registered at ClinicalTrials.gov (registration number: NCT02427958).

Conflict of interest statement

All remaining authors declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
Dosage regimen protocol.
Figure 2
Figure 2
Disposition of patients.

References

    1. The Subspecialty Group of Endocrinological, Hereditary and Metabolic Disease, the Society of Pediatrics, Chinese Medical Association, Editorial Board of the Chinese Journal of Pediatrics. Consensus on diagnosis and treatment of central precocious puberty. Zhonghua Er Ke Za Zhi 2015;53:412–8.
    1. Bangalore Krishna K, Fuqua JS, Rogol AD, et al. . Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr 2019;91:357–72.
    1. Carel JC, Eugster EA, Rogol A, et al. . Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752–762.
    1. Wheeler MD, Styne DM. The treatment of precocious puberty. Endocrinol Metab Clin North Am 1991;20:183–90.
    1. Lin Feng, Zheng Chang-Hua, Li Hua, et al. . Investigation and research about precocious puberty in eastern coast of Zhejiang Province. Shiyong Erke Linchuan Zazhi 2004;19:640–2.
    1. Cai DP. Progress of precocious puberty in children. J Appl Clin Pediatr 2005;20:497–9.
    1. Aguirre RS, Eugster EA. Central precocious puberty: from genetics to treatment. Best Pract Res Clin Endocrinol Metab 2018;32:343–54.
    1. Kaplowitz PB, Backeljauw PF, Allen DB. Toward more targeted and cost-effective gonadotropin-releasing hormone analog treatment in girls with central precocious puberty. Horm Res Paediatr 2018;90:01–7.
    1. Newton CL, Riekert C, Millar RP. Gonadotropin-releasing hormone analog therapeutics. Minerva Ginecol 2018;70:497–515.
    1. Bertelloni S, Baroncelli GI. Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties. Expert Opin Pharmacother 2013;14:1627–39.
    1. Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008;159: (Suppl 1): S3–8.
    1. China NHCotPsRo. Chinese precocious puberty treatment guideline 2010. 2010.
    1. Wang P-W, Hung Y-C, Wu T-H, Chen M-H, Yeh C-T, Pan T-L. Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis. Oncotarget 2017;8:88951–64.
    1. Li X, Wang F, Xu M, Howles P, Tso P. ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt signaling. Sci Rep 2017;7:41289.
    1. Tanka T, Naiki Y, Horikawa R. Evaluation of the dosage of LHRH analog in children with central precocious puberty. J Jpn Ass Hum Auxo 2010;16:85–92.
    1. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.
    1. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23.
    1. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. Stanford: Stanford University Press; 1971.
    1. Tanner JM, Healy M, Goldstein H, Cameron N. Assessment of Skeletal Maturity and Prediction of Adult Height (TW3 Method). London: W.B Saunders Company; 2001.
    1. Kendirci HN, Agladioglu SY, Bas VN, Onder A, Cetinkaya S, Aycan Z. Evaluating the efficacy of treatment with a GnRH analogue in patients with central precocious puberty. Int J Endocrinol 2015;2015:247386.
    1. Sagodi L, Solyom E, Lombay B, Almasi A, Vamosi I. Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty. Orv Hetil 2012;153:418–24.
    1. Willemsen RH, Elleri D, Williams RM, Ong KK, Dunger DB. Pros and cons of GnRHa treatment for early puberty in girls. Nat Rev Endocrinol 2014;10:352–63.
    1. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190–5.
    1. Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Tato L. Bone development during GH and GnRH analog treatment. Eur J Endocrinol 2004;151: (Suppl 1): S47–54.
    1. Yanovski JA, Rose SR, Municchi G, et al. . Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908–17.
    1. Manasco PK, Pescovitz OH, Blizzard RM. Local reactions to depot leuprolide therapy for central precocious puberty. J Pediatr 1993;123:334–5.
    1. Neely EK, Hintz RL, Parker B, et al. . Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr 1992;121:634–40.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren